Abstract
Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has become an established treatment for selected peritoneal surface malignancies. However, awareness, training exposure, and attitudes toward CRS-HIPEC vary among oncologic disciplines. This nation sample study aimed to assess and compare the knowledge, awareness, and perceptions of surgical and medical oncologists in Türkiye regarding CRS-HIPEC indications, benefits, and implementation. A cross-sectional, web-based survey was conducted between July and December 2025 among certified surgical and medical oncologists. A 19-item questionnaire evaluated demographics, CRS-HIPEC training exposure, institutional practices, and attitudes using a five-point Likert scale. A total of 98 oncologists participated (50 surgical, 48 medical), corresponding to an overall response rate of 36.3%. HIPEC-related training was significantly more common among surgical oncologists (39/50, 78% vs 13/48, 27%; p < 0.001), as were higher self-rated knowledge levels (p < 0.001) and awareness of CRS-HIPEC indications (40/50, 80% vs 28/48, 58%; p = 0.035). Agreement with the statement that CRS-HIPEC improves survival in appropriately selected patients was also stronger among surgical oncologists (44/50, 88% vs 35/48, 73%; p = 0.006). Among medical oncologists, those participating in multidisciplinary tumor boards were more likely to agree with the survival benefit (p = 0.032). Overall, 92% of participants supported the need for a national CRS-HIPEC guideline or standardized protocol. Surgical oncologists report greater training exposure and stronger belief in the benefit of CRS-HIPEC; however, multidisciplinary collaboration enhances understanding and acceptance among medical oncologists. Unified national guidelines and structured training programs may help align perspectives and optimize multidisciplinary practice.